drugset / Trial / NCT00000222

Alternate-Day Buprenorphine Administration. Phase II - 4

NCT00000222

CrossoverTreatment

Summary

The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Timeline

Start
1992-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified